Shengnuo Bio released its 2026 half-year report. Net profit attributable to the parent in the first half was 135 million yuan, up 52% year on year. Operating revenue was 507 million yuan, up 50.3% year on year. Net profit attributable to the parent after deducting non-recurring items was 134 million yuan, up 50.2% year on year. Net operating cash flow was 87.23 million yuan, up 6.8% year on year. Second-quarter operating revenue was 263 million yuan, up 71.6% year on year, and net profit attributable to the parent was 68.83 million yuan, up 64.5% year on year. As of the end of the second quarter, total assets were 2.072 billion yuan, up 7.1% from the end of the previous year, and net assets attributable to the parent were 1.144 billion yuan, up 8.2% from the end of the previous year. The company continued to advance research, development and production services for peptide innovative drugs, strengthened the conversion and delivery of peptide CDMO projects, and obtained marketing authorization approvals for multiple active pharmaceutical ingredients.
Cheng Du Sheng Nuo Biotec Co. Ltd. AFirst-half net profit up 52% and revenue up 50.3%, with strong Q2 growth.
